The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 10, 2019

Filed:

Jan. 04, 2017
Applicant:

Intrexon Corporation, Blacksburg, VA (US);

Inventors:

Robert E. Hormann, Elkins Park, PA (US);

Inna Shulman, Langhorne, PA (US);

Eva Rödel, Basel, CH;

Rolf Hilfiker, Allschwil, CH;

Susan M. De Paul, Zürich, CH;

Assignee:

INTREXON CORPORATION, Blacksburg, VA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 243/38 (2006.01); A01N 37/28 (2006.01); C07C 243/38 (2006.01); A01N 37/40 (2006.01); A61K 31/166 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); C07C 241/02 (2006.01);
U.S. Cl.
CPC ...
C07C 243/38 (2013.01); A01N 37/28 (2013.01); A01N 37/40 (2013.01); A61K 31/166 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); C07C 241/02 (2013.01); C07B 2200/07 (2013.01); C07B 2200/13 (2013.01); C12N 2710/10341 (2013.01); C12N 2830/002 (2013.01); Y02A 50/401 (2018.01); Y02A 50/409 (2018.01); Y02A 50/411 (2018.01); Y02A 50/423 (2018.01); Y02A 50/475 (2018.01); Y10T 428/2982 (2015.01);
Abstract

The present disclosure provides crystalline polymorphic and amorphous forms of (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) or (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of Compound 1 or Compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of Compound 1 or Compound 2, and methods of using crystalline polymorphic or amorphous forms of Compound 1 or Compound 2 to regulate gene expression in a cell or in a subject.


Find Patent Forward Citations

Loading…